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cense. httpAbstract Introduction: Gastrointestinal lymphoma (GIL) is the most common extranodal form of
non-Hodgkin’s lymphoma (NHL) with geographical and age variation of its various subtypes.
Aim: To study GIL in Gharbiah, Egypt and to recognize the treatments employed and their out-
comes including survival.
Methods: This is a retrospective study. Between 2000 and 2002, 40 adult patients with GIL were
identiﬁed in the Gharbiah population based cancer registry (GPBCR); 26 cases of whom were trea-
ted at Tanta Cancer Center (TCC).
Results: GIL in Gharbiah, Egypt represented 6.2% of all GIT cancers. The median age was
47 years with slight male predominance. The commonest primary site was the stomach followed
by the colon/rectum then the small intestine (67.5%, 25% and 7.5%, respectively). The commonest
histological subtypes were the diffuse large B-cell (41.5%) followed by marginal zone B-cell (39%).
The commonest symptoms were abdominal pains followed by vomiting. Only 18% of GILs were
surgically resected. Most patients (77%) received chemotherapy with a 60% complete response
(CR) rate. Once in CR, relapses are occasional. The median overall survival (OS) and progression
free survival (PFS) were 31 and 14 months (95% CI, 13.2–48.7 and 6.4–21.6 months, respectively).
Gastric primary site and diffuse large B cell subtype carry a non-signiﬁcant worse OS and PFS than
those of other sites and subtypes.rtment of Medical Oncology,
sity, Kasr Eleini St., Foum El-
om (M.A. Samra).
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96 M.M. Saber et al.Conclusions: GILs in Gharbiah, Egypt are characterized by predominance of male gender, gastric
site and marginal zone histology. Survival is worse for gastric and diffuse large B-cell GILs com-
pared to other sites and histologies.
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Gastrointestinal tract is the most common extranodal site in-
volved by lymphoma accounting for 5%–20% of all cases
[1,2]. However, primary gastrointestinal lymphoma (GIL) is
very rare, constituting only about 1%–4%of all gastrointestinal
malignancies. Although lymphoma can involve any part of the
gastrointestinal tract, the most frequent sites among adults are
the stomach followed by the small intestine and ileocecal region
[3]. In the pediatric age group, small and large intestines are the
most frequent sites [4].Diffuse largeB-cell (DLBC) lymphoma is
the most common pathological subtype in all sites of the gastro-
intestinal tract. Nevertheless, the frequency of other subtypes
has recently increased in certain regions of the world [3].
GILs can be associated with chronic inﬂammation that
forms the basis of understanding the mucosa associated lym-
phoid tissue (MALT) lymphomas. However, chronic inﬂam-
mation can also pose diagnostic difﬁculties [5,6]. While
chronic gastritis due to Helicobacter pylori is the best-studied
precursor of MALT lymphoma, other parts of the GIT dem-
onstrate precursor inﬂammatory lesions that lead to speciﬁc
types of lymphoma [7].
The diagnostic difﬁculties for GILs are compounded by the
fact that often only small biopsies are available for examina-
tion and the morphology of a particular type of lymphoma
may differ in the GIT compared to the lymph node. Several re-
cent large series describing the epidemiological and clinico-
pathological features of primary GIT lymphomas have been
published [3,8–14]. The advent of wireless capsule endoscopy
and double balloon enteroscopy has made previously inacces-
sible portions of GIT visible and changed our perceptions
about some types of GILs. Finally, the increasing number of
immunosuppressed patients (either due to HIV or iatrogenic)
is associated with increasing incidence of some types of GILs
that were very rarely seen previously [15–18].
Staging of GILs is a matter of debate due to various avail-
able staging systems. Although the modiﬁed Ann Arbor classi-
ﬁcation is feasible and relevant for prognosis, certain demerits
in terms of disseminated and incurable inﬁltration of the GIT
prompted development of the Paris staging system, which can
differentiate distant lymphoma manifestations depending on
the involved organ (using endoscopic ultrasound), and further
subdivide lymph node involvement [19].
In this retrospective study, we reviewed the clinicopatho-
logic characteristics and treatment outcomes of 40 adult pa-
tients with GIL identiﬁed at the Gharbiah population based
cancer registry (GPBCR) in Egypt.Methods
This is a retrospective study. Patients with GILs were identiﬁed
through GPBCR. Data on age, sex, sub-site, histology, grade,
stage and treating center were obtained from the registry.
Further data on complaints, comorbidities, treatment modali-ties (surgery, radiotherapy and chemotherapy), response to
therapy, dates of diagnosis, surgery and relapse; and survival
were obtained for that subset of patients treated at Tanta Can-
cer Center (TCC). The study was approved by the IRB of the
Egyptian National Cancer Institute.
Inclusion criteria were patients with GIL (site codes) and a
malignant histology [histology codes (ICD-O-3)] between 2000
and 2002. Exclusion criteria were non-conﬁrmed histologic
subtype as those diagnosed based on death certiﬁcate, radiol-
ogy or malignant neoplasm unspeciﬁed.
Between 2000 and 2002, 42 cases with GILs contained in
GPBCR were identiﬁed. Two cases were excluded; one diag-
nosed from death certiﬁcate and another had the diagnosis
of NHL with no subtype identiﬁed. Patients’ ﬁles were re-
viewed for clinical and pathologic data, details of treatments
and their outcome including response and survival.
Statistical analysis
All analyses were done using SPSS software program version
15 (Chicago, USA). Nominal and categorical data were com-
pared for different histologies (Diffuse large B vs. others)
and subsites (gastric vs. others) using the Chi squared test or
Fisher’s exact test. Survival was calculated using the Kaplan
Meier method and groups were compared using the Log-rank
test. A probability (p) < 0.05 (two sided) was considered sta-
tistically signiﬁcant.
Results
GPBCR patients
GILs represented 6.2% of GIT cancers in GPBCR. All GILs
were of the non-Hodgkin’s lymphoma (NHL) type. The med-
ian age was 47 years (range, 20–77 years) with slight male pre-
dominance (male to female ratio of 1.2:1). The stomach was
the commonest involved site followed by the colon/rectum
and small intestine (67.5%, 25% and 7.5%, respectively).
The gastric antrum and the cecum were the commonest sub-
sites. Most patients (29/40) had either local or regional disease.
Seven patients had a widespread disease to the liver (2 cases),
lungs (2 cases), bone (1 case) or unknown sites (2 cases). Dif-
fuse large B-cell (DLBC) subtype was the commonest subtype
(41.5%) followed by the marginal-zone B-cell (MZ) subtype
(39%). Other subtypes included diffuse mixed small and large
cell (3 cases), B-cell Small lymphocytic (2 cases), mantel cell (1
case) and follicular (1 case). Most DLBC (11/17) and MZ (13/
16) were located in the stomach. Table 1 shows the character-
istics of the 40 GIL patients identiﬁed through GPBCR.
Tanta Cancer Center (TCC) patients
We could identify 26 cases treated at TCC, the main oncology
center in Gharbiah governorate, Egypt. Their characteristics
Table 2 Treatment and response to treatment given for 26
patients with histologically conﬁrmed gastrointestinal NHL
treated at Tanta Cancer Center.
Treatment Number (%)
Clinical presentations
Abdominal pains 12 46.2
Vomiting and pains 7 26.9
Anemia 2 7.7
Intestinal obstruction 2 7.7
None/unknown 3 11.5
Surgery
Hemicolectomy 3 11.5
Small intestinal resection 1 3.8
No 22 84.7
Chemotherapy
Yes 21 80.8
No 5 19.2
Chemotherapy regimens
CHOP 14 66.6
CVP 7 33.4
Response
Complete response (CR) 12 57.1
Less than CR 7 33.4
Not assessed 2 9.5
CR: complete response; CHOP: cyclophosphamide, doxorubicin,
vincristine, prednisolone; CVP: cyclophosphamide, vincristine,
prednisolone.
Table 1 Clinico-pathologic characteristics of patients with histologically conﬁrmed gastrointestinal NHL at Gharbiah population
based cancer registry (GPBCR) and Tanta Cancer Center (TCC).
Characteristic GPBCR cases TCC cases Non-TCCcases P*
No. (%) No. (%) No. (%)
Total 40 100 26 100 14 100
Sex
Male 22 55.0 14 53.8 8 57.1
Female 18 45.0 12 46.2 6 42.9 0.84
Site
Gastric 27 67.5 18 69.3 9 64.3
Intestinal** 13 32.5 8 30.7 5 35.7 0.75
SEER stage 36 25 11
Localized 13 36.1 9 36.0 4 36.4
Non-localized 23 63.9 16 64.0 7 63.6 0.72
Regional 16 44.4 9 36.0 7 63.6
Distant 7 19.5 7 28.0 0 0
NHL histology subtype***
Diﬀuse large B-cell 17 41.5 10 38.4 7 50.0
Marginal zone B-cell 16 39.0 13 50.0 3 21.4 0.31
GPBCR: Gharbiah population based cancer registry; TCC: Tanta Cancer Center; SEER: Surveillance Epidemiology and End Results; NHL:
non-Hodgkin’s lymphoma.
* Fisher’s exact test.
** Intestinal sites include colon/rectum (no = 10) and small intestine (no = 3).
*** Other histologic subtypes (not included in the analyses) are diffuse mixed small and large cell (no = 3), B-cell Small lymphocytic (no = 2),
mantel cell (no = 1) and follicular NHLs (no = 1).
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(shown in Table 1). Unfortunately, clinical data particularly
pertaining to treatments and follow up were not contained in
GPBCR. Thus, we tried to further track as many cases as pos-
sible through reviewing cases that presented to TCC. Most
patents had symptoms related to their disease with abdominal
pains being the commonest (Table 2). Only four patients
underwent surgery and none received radiotherapy. More than
three quarters (21/26) of patients received chemotherapy. Che-
motherapy regimens used were CHOP in 14/21 patients and
CVP in 7/21 patients. The median number of cycles was 6
(range, 2–8). Twelve patients (57%) had a complete remission
(CR), seven had less than CR and the response was not ascer-
tained in two patients (Table 2). At the last visit, 10 patients
were in maintained CR, 12 patients had evidence of disease
progression and two patients had documented relapses that
were local in one patient and distant in the other. The relapse
free survival (RFS) ranged between 14 and 100 months and the
median was not reached. RFS at 16 months was 71.4% (SE,
17.1%).
The median follow-up period was 76 months (range, 1–
104 months). At the last documented visit, 12 patients were
alive; 10 were free of lymphoma and two with evidence of lym-
phoma. Meanwhile, 14 patients were dead. Deaths were dis-
ease related in 11 cases. The median overall survival (OS)
was 31 months (95% CI, 13.2–48.7 months) (Fig. 1). The med-
ian progression free survival (PFS) was 14 months (95% CI,
6.4–21.6 months) (Fig. 2).
OS and PFS according to various clinico-pathological fea-
tures are shown in Table 3. For different histological subtypes,
the median OS of BLBC GIL was 10 months compared to
64 months in MZ GIL (p= 0.57). The median PFS of BLBC
GIL was 6 months compared to 16 months in MZ GIL(p= 0.42). For different sites, the median OS of gastric site
was 26 months compared to 31 months in intestinal sites
(p= 0.57). The median PFS of gastric site was 10 months
Figure 1 Overall survival of the 26 patients with gastrointestinal NHL treated at Tanta Cancer Center (TCC).
98 M.M. Saber et al.compared to 16 months in intestinal sites (p= 0.94). Patients
who received CHOP had a median OS of 64 months compared
to 31 months in those who received CVP (p= 0.75). The med-
ian PFS was 64 months with CHOP compared to 9 months
with CVP (p= 0.48).
Discussion
In our series, GILs represented a minority of all GIT cancers
(6.2%), which is comparable to an incidence of 4% reported
by the literature [20–22].
Males were slightly more affected than females in our study
with a male to female ratio of 1.2:1 which is lower than what
has been reported from the West (1.74:1) [23]; Jordon
(2.8:1)[24]; and India (1.9:1) [20,25]; but it is close to the ratio
reported from Thailand (1.4:1) [26]; China (1.2:1) (1.18:1)
[27,28]; and Japan (1.2:1) [8].
The median age of patients in our study was 47 years. This
age was relatively younger than that shown in 2 studies from
China reporting a median age of 53 years [26,28]; and of
56 years in Singapore [29]. Other studies revealed younger
age of patients e.g. mean age 21 and 34 years in two studies
from India respectively [20,25] and of 35 years in Saudi Arabia
[30] reﬂecting the variable geographic characteristics of the dis-
ease. H. pylori infection, immunosuppression after solid-organ
transplantation, celiac disease, inﬂammatory bowel disease,
and human immunodeﬁciency virus (HIV) infection may be
risk factors for GILs [21]. Given the retrospective nature of
the current study, data on these risk factors especially H. pylori
infection were not documented.
The commonest symptoms in our series were abdominal
pains (46%) followed by vomiting (27%), similar to common
symptoms reported by other studies [25,27,31–34].A difference in prognosis and distribution of GILs has been
reported in Western and Middle Eastern countries. GILs were
reported to be located more frequently in the stomach in the
West, but more frequently in the small intestine in the East,
although this was shown to be contrary in the recent years. In-
creased incidence of GIL in the small intestine was thought to
be due to higher incidence of immunoproliferative small intes-
tinal disease in the Middle East [35]. Stomach is the common-
est involved site in our study (69%). This ﬁnding is comparable
to most studies of GILs [8,26–29,31,36,37] reporting gastric
involvement that ranges between 56% and 81%. Series from
Jordon [38]; Kuwait [39] and Nigeria [40] reported higher prev-
alence of small intestinal GILs. However, other investigators
from the Middle East i.e. Saudi Arabia, reported involvement
of gastric site in 51% of patients [30]. Unlike Cirillio et al. [37]
and Koniaris et al. [41], our large intestine GILs (27%) ex-
ceeded those of the small intestine (4%). Our low ﬁgures of
small intestinal GILs are mainly because of exclusion of pedi-
atric patients where intestinal GILs predominate [42,43]. This
may also be a random variation associated with a relatively
low number of cases.
Similar to most studies, diffuse large B-cell (DLBC) NHL
was the commonest subtype followed by marginal zone (MZ)
NHL [26–27,29,44]. In Japan, MZ subtype slightly exceeded
DLBC subtype [8] and this may reﬂect the geographic varia-
tion [33].
Similar to many studies [28–29,31], most patients (81%) of
the current study received chemotherapy. However, surgery
was less encountered in our study (16%) and this may reﬂect
temporal evolution of the treatment of GILs with a decreasing
role of surgery and increasing that of radiation therapy and
systemic therapy [8]. The complete response (CR) rate after
chemotherapy in our series was 57% which is comparable to
Figure 2 Progression-free survival of 26 patients with gastrointestinal NHL treated at Tanta Cancer Center (TCC).
Table 3 Overall survival (OS) and progression free survival (PFS) of patients with gastrointestinal NHL treated at Tanta Cancer
Center.
Variable No. OS PFS
Median
(months)
1-y rate (SE)
(%)
2-y rate (SE)
(%)
p Median
(months)
1-y rate (SE)
(%)
2-y rate (SE)
(%)
p
All patients 26 31 62 (10.1) 56 (10.6) – 14 51 (10.2) 41 (10.6) –
Sex
Female 12 26 70.0 (14.5) 58.3 (16.1) 0.95 10 45.8 (15.0) 27.5 (13.5) 0.41
Male 14 42 55.6 (13.6) 55.6 (13.6) 42 55.6 (13.6) 55.6 (13.6)
Site
Gastric 18 26 62.7 (12.1) 53.8 (13.3) 10 47.2 (12.1) 39.4 (12.4)
Intestinal 8 31 62.5 (17.1) 62.5 (17.1) 0.57 16 62.5 (17.1) 46.9 (18.7) 0.96
Histologic subtypes*
DLBC 10 10 44.4 (16.6) 44.4 (16.6) 6 40.0 (15.5) 26.7 (15.0)
MZ 13 64 65.3 (14.2) 65.3 (14.2) 0.37 16 56.3 (14.8) 45.0 (15.6) 0.42
Stage
I 9 64 58.3 (18.6) 58.3 (18.6) 64 51.9 (17.6) 51.9 (17.6)
II 9 42 50.8 (17.7) 50.8 (17.7) 10 44.4 (16.6) 44.4 (16.6)
IV 7 26 71.4 (17.1) 53.6 (20.1) 0.8 14 57.1 (18.7) 19.0 (16.8) 0.94
Chemotherapy regimen
CVP 7 31 66.7 (19.2) 66.7 (19.2) 9 50.0 (20.4) 25 (20.4)
CHOP 14 64 76.2 (12.1) 66.6 (13.8) 0.75 64 62.9 (13.3) 53.9 (14.1) 0.48
1-y rate: one-year rate; 2-y rate: two-year rate; SE: standard error; NR: not reached; MZ: marginal zone NHL; DLBC: diffuse large B cell NHL;
CVP: cyclophosphamide, vincristine, prednisolone; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone.
* Other histologic subtypes are not included in the analyses.
Primary GIL in Egyptian patients 99that seen in other studies [28–29,32,45] reporting CR rates that
range between 52% and 67%.
In our study, the median OS and PFS rates were 31 and
14 months respectively; and the two-year OS and PFS rateswere 56% and 41% respectively. Survival rates in the current
study were similar to those reported by many studies [29,32–
33,45–46]. Higher 2-year OS (67%) was reported in a study
from Singapore [29]. Also, Cirillio et al. [37] reported a median
100 M.M. Saber et al.OS of 54 months, with 46% of patients surviving at 5 years.
Liang et al. [28] reported the experience in the management
of 425 Chinese patients with primary GILs in Hong Kong over
a period of 18 years. The OS of all patients was 45% at 5 years.
Multivariate analysis revealed that age below 60 years, low
grade histology, stage I or II disease and absence of bulky tu-
mor were independent prognostic factors predicting better OS.
Similar to several studies [28,46,47], MZ subtype had a bet-
ter prognosis than other subtypes included in our study partic-
ularly DLBC.
In our study, gastric involvement had a better OS and PFS
than intestinal involvement. However, the difference did not
reach statistical signiﬁcance. In a 15-year review of 75 cases of
GILs from North India and after a mean follow-up of 4 years,
the 5-year OS rates were 34%, 25% and 16% for stages I, II,
or >II, respectively. The survival rate was signiﬁcantly better
for gastric location (44%) compared to other sites (24%)
(p< 0.01) [25]. The 30-year experience of primary GILs (49
cases) at the Cancer Institute, Madras, India revealed that 5-
year OS and DFS rates were 47% and 40%, respectively. There
was no overall signiﬁcant difference in survival between the dif-
ferent treatment groups. Stage, extent of surgical resection, re-
sponse to treatment, serosal involvement, multimodality
treatment, and performance status were signiﬁcant prognostic
factors. Achievement of complete remission and complete surgi-
cal resection were the most favorable independent prognostic
factors on multivariate analyses [45]. In a study of the 185 pa-
tients with primaryGILs fromSaudiArabia, patientswith intes-
tinal lymphoma had a 10-year survival rate of 48% comparable
to 53% in those with gastric lymphoma (p= 0.431) [30].
Our study has strengths and limitations. To the best our
knowledge, it is the ﬁrst study fromEgypt that addresses the issue
ofGILs on the population level. The retrospective nature implies
somemissing data as these data were originally collected for rea-
sons other than research.Moreover, the medical service in Egypt
is spannedamongmanyproviders like theministry of health,mil-
itary, educational aswell as private hospitalsmaking accessibility
to complete patients’ information in all of these settings a difﬁcult
task. However, the study accurately reﬂects the practice of the
oncology community within the jurisdictions of the study.
In conclusions, in our trial, GIT NHL represents 6.2% of
all GIT cancers. The median age is 47 years with slight male
predominance. The commonest primary site is the stomach
followed by the colon/rectum. The commonest histological
subtype is Marginal zone B-cell followed by the diffuse large
B-cell. Most patients are treated with chemotherapy that gives
60% complete response rate. Once in CR, relapses are occa-
sional. The median OS and PFS are relatively short as 31
and 14 months, respectively. Gastric primary site and diffuse
large B cell subtype carry a non-signiﬁcant worse OS and
PFS that other sites and subtypes. Better classiﬁcation of the
primary GILs and more reﬁned stratiﬁcation of the patients
according to the prognostic variables may allow individualiza-
tion of treatment. Prospective studies are essential to deﬁne the
underlying causative or risk factors as well as the relative roles
of surgery, chemotherapy and radiotherapy.
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